BeiGene’s aggressive expansion brings revenue jolt
The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year Key…
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
The Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant Key Takeaways: AstraZeneca…
Will Junshi Bio’s loss-making headaches ease with landmark U.S. drug approval?
The FDA has given the nod to the Chinese company’s PD-1 drug, but most of the benefits will go to a third-party licensee Key Takeaways: Junshi Bio will receive milestone…
FAST NEWS: Innovent Bio’s revenue soars on strong cancer treatment sales
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Thursday it recorded product revenue of more than 1.6 billion yuan ($2.2 million) in the third quarter, up 45% year-on-year, and also…
FAST NEWS: Burning Rock’s cancer test gets breakthrough designation
The latest: Cancer screening company Burning Rock Biotech Ltd. (BNR.US) announced Sunday that its OverC multi-cancer detection blood test (MCDBT) has been granted breakthrough device designation by the China National…
FAST NEWS: Innovent Bio to raise HK$2.4 billion in share placement
The latest: Biotech company Innovent Biologics Inc. (1801.HK) announced on Tuesday it will place 68 million new shares, representing approximately 4.22% of its enlarged share capital, to raise about HK$2.36 billion ($302 million).…
FAST NEWS: Luye Pharma’s Schizophrenia Drug Wins FDA Approval
The latest: Drug maker Luye Pharma Group Ltd. announced Sunday that its drug Rykindo has been approved by the U.S. Food and Drug Administration (FDA) as a treatment for schizophrenia…
Recent Articles
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
